Answers are grounded in this paper and cite their sources.
Background 68 Ga-DOTA0-Tyr3-octreotide ( 68 Ga-DOTATOC) positron emission tomography–CT (PET-CT) has superior diagnostic performance compared to the licensed tracer OctreoScan single photon emission CT–CT in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). A new preparation of 68 Ga-DOTATOC using a new ‘ready-to-use' 68 Ga-DOTATOC formulation for injection has been developed ( 68 Ga-DOTATOC (SomaKIT TOC)). Objectives This study aimed to assess the safety and tolerability of 68 Ga-DOTATOC (SomaKIT TOC) and evaluate the feasibility and robustness of implementing it in a NET clinical imaging service. Methods A first-in-human phase I/II multicentre, open-label study of a single dose of 68 Ga-DOTATOC (SomaKIT TOC) 2 MBq/kg±10% (range 100–200 MBq) in patients with biopsy-proven grade 1–2 GEP-NETs. PET-CT was performed post injection. Patients were followed up for 28 days. We next implemented this new synthesis methodology in a clinical service assessed over 11 months. Results Twenty consenting patients were recruited; 14 males, 6 females; mean (SD) age 58 years (12); NET grade 1 (70%), grade 2 (30%); and 75% with stage IV disease. Twelve patients experienced at least one adverse event (AE) during the study with no grade 3–4 toxicities. Only four AEs were classified as possibly (headache (n=1; 4%), nausea (1; 4%)) or probably (dysgeusia (1; 4%), paraesthesia (1; 4%)) related to the study preparation. One hundred thirteen vials of 68 Ga-DOTATOC (SomaKIT TOC) were synthesised with the ‘kit' over a period of 11 months for clinical utility. Only 2/113 vials (1.77%) were rejected. Conclusions The new ready-to-use preparation of 68 Ga-DOTATOC (SomaKIT TOC) for injection was safe and well tolerated. This has led to the world's first (EMA) licensed 68 Ga-DOTATOC (SomaKIT TOC) radiopharmaceutical for the utility of PET imaging in patients with NETs. This preparation can be robustly implemented into routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Manoharan et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: